Valuation: Seres Therapeutics, Inc.

Market Cap 74.95M 65.52M 60.22M 56.13M 106M 7.14B 108M 723M 281M 3.51B 281M 275M 12.09B P/E 2026 *
-1.03x
P/E 2027 * -1.18x
Enterprise Value 74.95M 65.52M 60.22M 56.13M 106M 7.14B 108M 723M 281M 3.51B 281M 275M 12.09B EV / Sales 2026 *
5.83x
EV / Sales 2027 * 209x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-2.52%
1 week+9.32%
Current month-1.90%
1 month+12.99%
3 months-16.50%
6 months-48.91%
Current year-47.98%
1 week 7.07
Extreme 7.07
8.06
1 month 5.31
Extreme 5.31
8.06
Current year 5.31
Extreme 5.31
16.42
1 year 5.31
Extreme 5.31
29.98
3 years 5.31
Extreme 5.31
105.8
5 years 5.31
Extreme 5.31
440.3
10 years 5.31
Extreme 5.31
770
Manager TitleAgeSince
Chief Executive Officer 70 2026-03-01
President 51 2026-03-01
Chief Executive Officer 58 2025-07-31
Director TitleAgeSince
Chairman 70 2026-03-01
Director/Board Member 50 2019-01-14
Director/Board Member 80 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,508 0.0775%
06-30Free

Director

7,508 0.0775%
06-30Free

Director

7,508 0.0775%
Change 5-day change 1-year change 3-year change Capi.($)
-2.52%+9.32%-34.79%-92.10% 74.95M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.33%+9.02%+45.34%+120.79% 24.56B
Weighted average by Cap. +2.46%+6.48%+58.30%+136.90%

Financials

2026 *2027 *
Net sales 12.86M 11.24M 10.33M 9.63M 18.26M 1.22B 18.54M 124M 48.21M 602M 48.26M 47.23M 2.07B 358K 313K 288K 268K 508K 34.09M 516K 3.45M 1.34M 16.76M 1.34M 1.31M 57.74M
Net income -70.97M -62.04M -57.01M -53.14M -101M -6.76B -102M -684M -266M -3.32B -266M -261M -11.45B -99.82M -87.27M -80.2M -74.75M -142M -9.5B -144M -963M -374M -4.67B -375M -367M -16.1B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
26-07-02 US$7.740 -2.52% 130,834
26-07-01 US$7.940 +0.63% 150,876
26-06-30 US$7.890 +1.28% 113,846
26-06-29 US$7.790 +10.03% 131,503
26-06-26 US$7.080 +3.43% 301,492
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.740USD
Average target price
17.00USD
Spread / Average Target
+119.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock